{Reference Type}: Journal Article
{Title}: Nomogram models predicting prognosis for patients with t(8;21) acute myeloid leukemia: a SEER-based study.
{Author}: Yang J;Zhu X;Zhang H;Fu Y;Li Z;Xing Z;Yu Y;Cao P;Le J;Jiang J;Li J;Wang H;Qian M;Zhai X;
{Journal}: Hematology
{Volume}: 29
{Issue}: 1
{Year}: 2024 Dec
{Factor}: 2.264
{DOI}: 10.1080/16078454.2024.2381169
{Abstract}: <B>UNASSIGNED: </B>Acute myeloid leukemia (AML) with t(8;21) manifests as a diverse hematological malignancy. Although it was categorized into a favorable subtype, 30-40% of patients experience relapse. The objective of this research was to devise a nomogram for the accurate anticipation of both overall survival (OS) and cancer-specific survival (CSS) in t(8;21) AML.<BR><B>UNASSIGNED: </B>From the Surveillance, Epidemiology, and End Results (SEER) database, individuals diagnosed with t(8;21) AML from 2000 to 2018 were selected. Prognostic factors for t(8;21) AML were identified using Cox regression analysis and Akaike Information Criterion (AIC), forming the basis for constructing prognostic nomograms.<BR><B>UNASSIGNED: </B>Key variables, including first primary tumor, age group, race, and chemotherapy, were identified and integrated into the nomogram. The C-index values for the nomograms predicting OS and CSS were 0.753 (validation: 0.765) and 0.764 (validation: 0.757), respectively. Ultimately, based on nomogram scores, patients were stratified into high-risk and low-risk groups, revealing significant disparities in both OS and CSS between these groups (P < 0.001).<BR><B>UNASSIGNED: </B>This study innovatively crafted nomograms, incorporating clinical and therapeutic variables, to forecast the 1-, 3-, and 5-year survival rates for individuals with t(8;21) AML.